Nov 03, 2014 8:35am EST SCYNEXIS, Inc. Enters Into Worldwide Agreement With Waterstone Pharmaceutical for the Development and Commercialization of SCY-635 for Viral Diseases
Jun 16, 2014 8:30am EDT SCYNEXIS Provides Update on Corporate Progress and First Quarter 2014 Financial Results
Feb 21, 2014 8:00am EST SCYNEXIS Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA for Antifungal Agent SCY-078 for Oral Use